ReviewCancer medicine2023
Role of tumor microenvironment in cancer progression and therapeutic strategy.
Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 264 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
264 citing papers in PubMed, 1 synthesis or guideline pooled it, 388 citations in OpenAlex.
- Life Course Trajectories of Body Mass Index and Risk of Cancer in Adulthood: Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- Tumor microenvironment-responsive conformational activation of apoA-I mimetic peptides for targeted cancer therapy.Drug delivery · 2026Article
- IL-37/IL-1R8 axis: a novel major mechanism of control at the interface between tumor and immune cells.Oncoimmunology · 2026Review
- The expanding role of biocompatible hydrogels in plant-derived exosome-like nanovesicles for skin diseases: prospects and challenges.Annals of medicine · 2026Review
- Investigation of exercise-mimetic bioactive molecules as modulators of MMP activity and expression in cancer cells.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Bone niche-driven antitumor immune failure in osteosarcoma: Mechanisms and therapeutic implications (Review).Oncology letters · 2026Review
- Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.Molecular therapy. Oncology · 2026Article
- Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG-TGF-β signaling.Molecular therapy. Oncology · 2026Article
- Explainable AI-Assisted Label-Free Raman Biosensing Reveals Therapy-Associated Spectral Signatures in Melanoma Tumors.Biosensors · 2026Article
- The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success.Biology · 2026Review
- Obesity-driven adipokine signaling in breast cancer: mechanistic insights, therapeutic challenges, and opportunities for precision oncology.Journal of pathology and translational medicine · 2026Article
- M2‑TAM‑derived exosomal miR‑491‑3p modulates UBE2D3 and promotes the proliferation, migration and invasion of lung cancer cells.Oncology reports · 2026Article
- Single-Cell RNA-Seq Reveals Chromosomal Instability-Associated Transcriptomic Profiles in Breast Cancer.Biomedicines · 2026Article
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.Cancer science · 2026Article
- Article
- Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression.International journal of molecular sciences · 2026Review
- Article
204 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body's immune system. It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death-1 (PD-1), programmed death-1 ligand-1 (PD-L1), and programmed death Ligand-2 (PD-L2), the construction of antigen chimeric T cells (CAR-T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME. Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD-1 and TME, and promising cancer immunotherapy therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.